Study wrapper · #841
Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.
Editor's note
This small real-world cohort is squarely about semaglutide for weight management and usefully documents how everyday practice diverges from the trial protocol. In one Danish general practice, 206 adults (76% women, mean weight 105 kg) were prescribed semaglutide between 2022 and 2024. By 12 months, 38% had permanently stopped and another 15% had paused — only about half remained on treatment — and among continuers many stayed on lower-than-labeled maintenance doses (40% at ≤1.0 mg/week). Yet those who stayed on lost a substantial 13.6% of body weight, close to trial-level results. The honest tension: real-world titration is slower and doses lower than the label, and discontinuation is common, but persisters still did well. Caveats are significant — a single-practice sample of 206 is small, the weight-change figure covers only continuers with paired measurements (survivor bias), and there's no comparator. Weight it as an instructive snapshot of real-world semaglutide use, not as generalizable effectiveness data.
Plain-language abstract
This study looked at how semaglutide is actually used for weight loss in everyday care, compared with how it was used in the clinical trials. Researchers reviewed records from one general practice in Denmark for 206 adults (about three-quarters women, average weight 105 kg) prescribed semaglutide for weight management between December 2022 and May 2024. After one year, about 38% had stopped the drug for good and another 15% had paused it, leaving roughly half still taking it. Among those still on treatment, many were using lower weekly doses than the official label suggests, and doses were increased more slowly than the recommended schedule. Even so, people who stayed on the drug lost an average of about 13.6% of their body weight over the year — a substantial amount close to trial results. Important limits: this was a small group from a single clinic, there was no comparison group, and the weight-loss figure only includes people who kept taking the drug and had before-and-after weights, which can make results look better than they would across everyone who started.